Post_template - Page 8 of 10

World Congress on Inflammation, June 5–8, 2022, Rome, IT

Meet our Director Preclinical Development & Project Lead Inflammation, Christine Landlinger & Maroua Ferhat, Research Scientist at the WCI22 in Rome. Be sure to visit Christine’s talk on our inflammation candidate ON104 to learn more.

PEGS Boston, May 2–6, 2022, Boston, MA, US

Our CSO, Michael Thiele will be leading a session entitled “A New Immunotherapy Target: Co-Development of a Therapeutic Antibody and a Radioimmune Diagnostic Targeting Oxidized Macrophage Migration Inhibitory Factor (oxMIF)” at the PEGS, Boston, US.

12th Clinical Biomarker & CDx Summit Europe, April 27–28, 2022, London, UK

OncoOne’s CEO Randolf Kerschbaumer will give a talk on “oxMIF as a novel biomarker and immuno-oncology therapeutic target for precision medicine”, at the 12th Clinical Biomarker & CDx Summit Europe; April 27–28, London, UK.

OncoOne Presents Preclinical Proof of Concept Data for its Next-Generation oxMIF-targeted Monoclonal Antibody ON203 at the AACR Annual Meeting

PDF Vienna, Austria – April 8, 2022 – OncoOne, a biotechnology company focused on discovering precision medicines for cancer and autoimmune diseases, announced today the presentation of preclinical proof-of-concept data on its lead candidate ON203, a therapeutic monoclonal antibody targeting oxMIF, and the radiodiagnostic 89Zr-ON102,

AACR Annual Meeting, April 08–13, 2022, New Orleans, US

OncoOne will present its latest development for the treatment of solid tumors and lead candidate ON203 live at the AACR in New Orleans. Visit us at our poster presentation on Sunday, April 10th in Exhibit Halls D-H, Section 21, Poster # 313, and meet OncoOne’s

BIO Europe Spring Digital Event, March 28–31, 2022

Meet our CBO, Brent Meadows, CEO, Randolf Kerschbaumer, and CSO, Michael Thiele, at the digital BIO-Europe Spring 2022 to learn more about OncoOne’s novel therapies for the treatment of solid tumors and inflammatory/autoimmune diseases.

BIO CEO & Investors Conference, February 14th, 2022, New York, NY, US

Our CEO Randolf Kerschbaumer and our CBO Brent Meadows will attend in person at the hybrid 2022 BIO CEO & Investor Conference in NYC. Randolf will present OncoOne’s corporate highlights and progress live at 10am EST on February 14th, 2022.

OncoOne and GenScript ProBio Enter Agreement for the Manufacturing of Monoclonal Antibody Drugs Targeting oxMIF.

PDF Vienna, Austria – April 8, 2022 – OncoOne, a biotechnology company focused on discovering precision medicines for cancer and autoimmune diseases, announced today the presentation of preclinical proof-of-concept data on its lead candidate ON203, a therapeutic monoclonal antibody targeting oxMIF, and the radiodiagnostic 89Zr-ON102,

9th Annual Immuno-Oncology Summit, October 4–6th, 2021, Boston, MA, US

Meet our new CBO, Brent Meadows, at CHI’s 9th Annual Immuno-Oncology Summit in Boston to learn more about OncoOne’s pipeline of novel, anti-cancer therapies for the treatment of solid tumors and inflammation. Please visit OncoOne at poster #6 entitled “Harnessing oxidized macrophage migration inhibitory factor

OncoOne Appoints Brent Meadows as Chief Business Officer

Company establishes U.S. subsidiary as base for strategic partnerships and business development activities- PDF Vienna, Austria – September 15, 2021 – OncoOne, a biotechnology company focused on discovering precision medicines for cancer and other indications, announced today the appointment of Brent Meadows to its executive